Thymic large cell neuroendocrine carcinoma: report of a resected case - a case report
© Ogawa et al; licensee BioMed Central Ltd. 2010
Received: 18 August 2010
Accepted: 22 November 2010
Published: 22 November 2010
Thymic large cell neuroendocrine carcinomas (LCNECs) are very rare. We here describe a case in which the tumor could be completely resected. A 55-year-old male was admitted to our hospital for treatment of an anterior mediastinal tumor found at a regular health check-up. The patient underwent an extended thymectomy of an invasive thymoma of Masaoka's stage II that had been suspected preoperatively. The tumor was located in the right lobe of the thymus and was completely resected. Final pathological diagnosis of the surgical specimen was thymic LCNEC. The patient underwent adjuvant chemotherapy with irinotecan and cisplatin in accordance with the diagnosis of a lung LCNEC, and is alive without recurrence or metastasis 16 months after surgery.
Primary thymic neuroendocrine carcinomas (NECs) were categorized under the rubric of 'thymomas' until 1972, when Rosai and Higa suggested that these tumors were sufficiently distinctive to warrant classification as carcinoid tumors . Thymic NECs are relatively rare neoplasms that account for only approximately 2% to 4% of all anterior mediastinal neoplasms . In 1999, the World Health Organization established thymic epithelial tumor criteria and reclassified thymic carcinoma, referring to NECs as a subtype . In particular, the LCNEC was subclassified in the thymic NECs in accordance with the classification of pulmonary neuroendocrine tumors. Detailed clinical features of thymic LCNECs are still unknown, however, because of their rareness. We described a case with a review of the literature, focusing on the most likely optimal treatment it.
Under the diagnosis of invasive thymoma or thymic carcinoid, the patient underwent an extended thymectomy. The tumor was intraoperatively revealed in the right lobe of the thymus without any invasion to the adjacent organs:the aorta, superior vena cava, pericardium, bilateral phrenic nerve, or the right lung. Because the tumor had invaded the right parietal pleura, we also resected the right parietal pleura with a sufficient surgical margin.
Macroscopically, the elastic soft tumor surrounded by thymic fat tissue was 40 × 35 × 28 mm in size. The cut surface was mainly whitish-yellow in color and showed focal necrosis and red bloody spots.
The patient underwent adjuvant chemotherapy based on a platinum doublet containing cisplatin at 60 mg/m2 and irinotecan at 60 mg/m2 for three courses, and is alive without recurrence or metastasis at 16 months after surgery.
The neuroendocrine subtype of thymus tumors is defined on the basis of histopathological features and immunophenotypes. In recent studies [4, 5], NECs have been morphologically categorized into four main types: typical carcinoid, atypical carcinoid, LCNEC, and small-cell carcinoma. To our knowledge, LCNECs and small-cell carcinomas are highly malignant and have a poorer prognosis than do other thymic epithelial tumors. The LCNEC is included as a separate entity because of differences from carcinoids in survival rates as well as its incidence and clinical, epidemiologic, histological, and molecular characteristics.
Although chest CT and MRI revealed no invasion to the superior vena cava or the innominate vein in the present case, and T1- and T2-weighted images demonstrated isointensity, the tumor was highly suspected of having invaded the normal thymic tissue due to its unclear rim. Therefore, our preoperative diagnosis was an invasive thymoma or a carcinoid.
For optimal treatment, an accurate pretherapeutic diagnosis is important. However, as a thymic tumor is not always morphologically homogeneous, this may be difficult with a standard needle biopsy. Surgery offers the best chance for a definitive diagnosis and curative treatment of thymic tumors. The differential diagnosis for the anterior mediastinum includes other primary mediastinal tumors, mainly thymoma, paraganglioma, lymphoma, parathyroid adenoma or carcinoma, as well as medullary carcinoma of the thyroid. The most difficult but most important differential diagnosis in this setting is with thymoma, particularly of the spindle cell type. This latter can often show areas displaying a prominent neuroendocrine appearance with abundant epithelial cells disposed radially around an empty space closely simulating the microacinar growth pattern sometimes observed in carcinoids. To make a successful differential diagnosis, immunohistochemical staining can be helpful. Even though both types of lesions share strong CAM 5.2 positivity, thymomas are negative for neuroendocrine markers (e.g. chromogranin A, synaptophysin, NCAM, and CD56) and may be useful for NECs .
The case report of thymic LCNECs in Japan
4 M Recurrence
7 M Recurrence
4 M Recurrence
4 M Recurrence
6 M Recurrence
Currently, there is no evidence to support the use of postoperative therapy for Thymic LCNECs. Recent studies [12–14] of LCNEC of the lung recommended postoperative administration of adjuvant chemotherapy with platinum-based combination regimens (e.g. etoposide and others), which is the regimen for small cell lung carcinoma similar to the clinicopathologic and biologic features of LCNEC. Their results showed good prognosis. Platinum-based combination regimens were effective for the patients with LCNEC in their studies. Likewise, we believe that surgery and adjuvant therapy are needed to treat LCNEC in the thymus. Therefore we selected the regimen, cisplatin/irinotecan, for small cell lung carcinoma because Noda et al. revealed that cisplatin/irinotecan provided better results than did cisplatin/etoposide . And Fujiwara et al.  also indicated that irinotecan-based regimens might be as active against LCNEC of the lung as against SCLC. Since recurrence of thymic LCNECs occurs within a short duration after surgery and their prognosis is very poor, we regarded this disease as having an extensive status at resection. Therefore, we selected the regimen, cisplatin/irinotecan. However, the odalities for adjuvant chemotherapy remain to be defined.
Because primary thymic LCNECs are very rare, and the patients'prognoses are very poor, along with the lack of experience, a standardized treatment protocol, and the limited literature, all these contributing factors make it a difficult tumor to treat. Additional studies area warranted to determine the optimal treatment of thymic LCNECs.
Written informed consent was obtained from patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Part of this study was supported by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (No.20591676), as well as a grant from the Ministry of Health, Labour and Welfare, Japan (No.19-12).
- Rosai J, Higa E: Mediastinal endocrine neoplasm of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. Cancer. 1972, 29: 1061-1074. 10.1002/1097-0142(197204)29:4<1061::AID-CNCR2820290456>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
- Wick MR, Rosai J: Neuroendocrine neoplasms of the mediastinum. Semin Diagn Pathol. 1991, 8: 35-51.PubMedGoogle Scholar
- Rosai J: Histological Typing of the Thymus. World Health Organization International Histological Classification of tumours. 1999, Berlin: Springer-Verlag, 2Google Scholar
- Chetty R, Batitang S, Govender D: Large cell neuroendocrine carcinoma of the thymus. Histopathology. 1997, 31: 274-276. 10.1046/j.1365-2559.1997.2380849.x.View ArticlePubMedGoogle Scholar
- Moran CA, Suster S: Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol. 2000, 114: 100-110-View ArticlePubMedGoogle Scholar
- Cesar AM, Saul S: Neuroendocrine carcinomas (carcinoid tumor) of the thymus. Am J Clin Pathol. 2000, 114: 100-110-Google Scholar
- Mega S, Oguri M, Kawasaki R, Hazama K, Iwai K, Kondo S: Large-cell neuroendocrine carcinoma in the thymus. Gen Thorac Cardiovasc Surg. 2008, 56: 566-569. 10.1007/s11748-008-0299-7.View ArticlePubMedGoogle Scholar
- Tiffet O, Nicholson AG, Ladas G, Sheppard MN, Goldstraw P: A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest. 2003, 124: 141-146-10.1378/chest.124.1.141.View ArticlePubMedGoogle Scholar
- Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M, Koja K, Kinjo T, Adachi G, Murayama S: Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer. 2002, 94: 3115-3119-PubMedGoogle Scholar
- Dutta R, Kumar A, Jindal T, Mathur SR: Neuroendocrine carcinoma of the thymus gland with sternal invasion. Interact CardioVasc Surg. 2009, 8: 694-696. 10.1510/icvts.2008.201020.View ArticleGoogle Scholar
- Takezawa K, Okamoto I, Fukuoka J, Tanaka K, Kaneda H, Uejima H, Yoon HE, Imakita M, Fukuoka M, Nakagawa K: Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production. J Thorac Oncol. 2008, 3: 187-189. 10.1097/JTO.0b013e3181623359.View ArticlePubMedGoogle Scholar
- Iyoda A, Hiroshima K, Moriya Y, Takiguchi Y, Sekine Y, Shibuya K, Iizasa T, Kimura H, Nakatani Y, Fujisawa T: Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006, 82: 1802-1807. 10.1016/j.athoracsur.2006.05.109.View ArticlePubMedGoogle Scholar
- Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM, Brambilla E: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR alpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005, 23: 8774-8785. 10.1200/JCO.2005.02.8233.View ArticlePubMedGoogle Scholar
- Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, Nakatani Y, Yoshino I: Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2009, 138: 446-453. 10.1016/j.jtcvs.2008.12.037.View ArticlePubMedGoogle Scholar
- Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N: Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002, 346 (2): 85-91. 10.1056/NEJMoa003034.View ArticlePubMedGoogle Scholar
- Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yamada K, Tamura T: Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 2007, 37 (7): 482-486. 10.1093/jjco/hym053.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.